Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Aldosterone blockade in heart failure.

Allan D Struthers¹

¹Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. a.d.struthers@dundee.ac.uk

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS

|November 5, 2004

Summary

Aldosterone blockade, using drugs like spironolactone and eplerenone, significantly reduces mortality risk in heart failure patients. These aldosterone antagonists are crucial for managing severe heart failure and post-myocardial infarction complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial.

PloS one·2024

Same author

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.

Health technology assessment (Winchester, England)·2024

Same author

Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.

PloS one·2023

Same author

ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.

PloS one·2023

Same author

Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework.

The Lancet regional health. Europe·2023

Same author

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.

Lancet (London, England)·2022

Area of Science:

Cardiology
Pharmacology
Internal Medicine

Background:

Aldosterone significantly contributes to heart failure pathophysiology.
Standard treatments like ACE inhibitors may not fully suppress aldosterone.
Unchecked aldosterone promotes adverse cardiac remodeling and dysfunction.

Purpose of the Study:

To evaluate the efficacy of aldosterone blockade in heart failure.
To assess the impact of spironolactone and eplerenone on patient outcomes.

Main Methods:

The Randomized Aldactone Evaluation Study (RALES) compared spironolactone to placebo in severe heart failure.
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) compared eplerenone to placebo in post-MI patients with LV dysfunction.

Related Experiment Videos

Main Results:

Spironolactone reduced all-cause mortality by 30% and cardiac mortality by 31% in RALES.
Eplerenone reduced all-cause mortality by 15% and cardiovascular events by 13% in EPHESUS.
Both studies showed significant reductions in cardiac and sudden death risks.

Conclusions:

Aldosterone blockade is a vital component of optimal heart failure therapy.
Spironolactone and eplerenone offer significant survival benefits.
Targeting aldosterone pathways improves outcomes in heart failure and post-MI patients.